Evidence map›Paper›PMID 40052199›Full record

ArticleJournal of medical virology2025

HPV Biomarkers in Oral and Blood-Derived Body Fluids in Head and Neck Cancer Patients.

Luisa Galati, Marta Tagliabue, Tarik Gheit, Rita De Berardinis, Fausto Maffini, Sandrine McKay-Chopin, Giuseppe De Palma, Stefania Vecchio, Angelo Virgilio Paradiso, Laura Sichero and 16 more

Abstract read
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Luisa GalatiDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Marta TagliabueDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-7879-4846
Tarik GheitInternational Agency for Research on Cancer (IARC), Lyon, France.
Rita De BerardinisDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0003-4959-587X
Fausto MaffiniDepartment of Surgical Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-4554-8956
Sandrine McKay-ChopinInternational Agency for Research on Cancer (IARC), Lyon, France.
Giuseppe De PalmaExperimental Oncology and Biobank Management Unit, Institutional BioBank, IRCCS Istituto Tumori Giovanni Paolo II Bari, Bari, Italy.
Stefania VecchioIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Angelo Virgilio ParadisoExperimental Oncology and Biobank Management Unit, Institutional BioBank, IRCCS Istituto Tumori Giovanni Paolo II Bari, Bari, Italy.
Laura SicheroCenter for Translational Research in Oncology, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo FMUSP HC, Sao Paulo, Sao Paulo, Brazil.ORCID 0000-0002-7999-5818
Luisa Lina VillaCenter for Translational Research in Oncology, Instituto do Cancer do Estado de Sao Paulo ICESP, Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo FMUSP HC, Sao Paulo, Sao Paulo, Brazil.
Francesco ChuDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Francesco BandiDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Chiara MossinelliDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Jacopo ZocchiDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Giacomo PietrobonDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Stefano Filippo ZorziDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Enrica GrossoDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Stefano RiccioDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Roberto BruschiniDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Gioacchino GiuglianoDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Giovanni BlandinoTranslational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute, Roma, Italy.
Maria Lina TorneselloMolecular Biology and Viral Oncology Unit, IRCCS Istituto Nazionale dei Tumori "Fondazione G. Pascale", Napoli, Italy.
Mohssen AnsarinDivision of Otolaryngology and Head and Neck Surgery, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Massimo TommasinoInternational Agency for Research on Cancer (IARC), Lyon, France.
Susanna ChioccaDepartment of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.ORCID 0000-0002-9721-0850

Funding

We thank the Funders: Italian Ministry of Health with Ricerca Corrente, Reti RCR-2020-23670066, and 5 × 1000 funds, Alliance Against Cancer (ACC) Head and neck tumors, (WP 5), Fondazione AIRC per la Ricerca sul Cancro ETS to S. Chiocca (IG 2022 ID 27043). Luisa Galati was supported by a Fondazione Umberto Veronesi fellowship.World Health Organization 001
6 · The paper itself

Abstract

Oral HPV DNA and circulating tumor (ct) HPV DNA in plasma were evaluated as potential biomarkers for HPV-associated head and neck cancer (HNC). Samples from HNC patients (n = 132), including 23 oropharyngeal cancers (OPC), and non-HNC controls (n = 10) were analyzed. HPV status was determined using a multiplex bead-based test (E7-MPG) applied to formalin-fixed paraffin-embedded (FFPE) tissues (n = 90), plasma (n = 141), gargle samples (n = 141), and oral swabs (n = 142). HPV DNA was detected in 25.8% of HNC tissues, 12% of plasma samples, 20.6% of gargles and 7% of oral swabs with HPV16 as the most prevalent genotype. Among OPC cases, HPV16 DNA was found in 71.4% of FFPE samples. High concordance was observed between paired OPC tissues and plasma (91.3%) or gargles (95.2%), with moderate concordance for oral swabs (59.1%). Gargle samples alone demonstrated a 100% detection rate for HPV16-positive OPC, regardless of the cT stage, outperforming plasma (86.7%). Combined oral gargle and plasma analyses detected all HPV-positive OPC cases (7/7) at the early cT1 stage. These findings highlight the limited involvement of HPV in non-oropharyngeal HNC compared to OPC, and support gargle and plasma samples as minimally invasive diagnostic tools for detecting HPV-associated OPC.

Indexed as

Body FluidsHead and Neck NeoplasmsMouthPapillomaviridaePapillomavirus InfectionsAdultAgedAged, 80 and overBiomarkersDNA, ViralFemaleHuman papillomavirus 16HumansMaleMiddle AgedBiomarkersDNA, Viralbiomarkersbody fluidsHead and neck squamous cell carcinomahead neck cancerHPVHPV16HPV DNAoropharyngeal cancerplasmasaliva

Identifiers

PMID40052199
PMCPMC11886502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.